JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
JNCE
Delisted
JNCE was delisted on the 3rd of May, 2023.
100 hedge funds and large institutions have $221M invested in Jounce Therapeutics, Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 30 increasing their positions, 24 reducing their positions, and 8 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
4% more call options, than puts
Call options by funds: $876K | Put options by funds: $839K
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Holders
100
Holding in Top 10
2
Calls
$876K
Puts
$839K
Top Buyers
| 1 | +$4.37M | |
| 2 | +$4.13M | |
| 3 | +$3.15M | |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$2.27M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.75M |
Top Sellers
| 1 | -$4.69M | |
| 2 | -$1.62M | |
| 3 | -$1.16M | |
| 4 |
Millennium Management
New York
|
-$823K |
| 5 |
SO
STRS Ohio
Columbus,
Ohio
|
-$757K |